Is radioiodine ablation with 1.1 GBq (30 mCi) 131I necessary in low-risk thyroid cancer patients? Results from a long-term follow-up prospective study
Background In patients with low-risk differentiated thyroid cancer (DTC), remnant ablation with radioiodine (RA) after total thyroidectomy (TT) is controversial. No benefits have been demonstrated in terms of mortality or disease-free survival. Recent evidence found that RA did not improve mid-term outcomes. Purpose To evaluate initial response to treatment and long-term follow-up status in low-risk DTC patients after TT vs. TT + RA with 131I 1.11 GBq (30 mCi). Methods Prospective multicenter non-randomized study; 174 low-risk DTC that underwent TT were recruited an divided in two groups according to RA (87 ablated and 87 non-ablated). Response to treatment was evaluated at 6–18 months after thyroidectomy and at the end of follow-up with measurements of thyroglobulin, and anti-thyroglobulin antibodies levels, and neck ultrasonography. Results Baseline characteristics of both groups were similar. Ablated patients: median age 45.5 years, 84% females, 95.4% papillary thyroid carcinoma (PTC), mean tumor size 16 mm; non-ablated: median age 45 years, 88.5% females, 96.6% PTC, mean tumor size 14 mm. Response to initial treatment was similar between both groups, with < 2% of structural incomplete response. Final status was evaluated in 139 cases (median follow-up of 60 months). Among ablated patients, 82.8% had no evidence of disease (NED), 12% had an indeterminate response (IR) and 5% a biochemical incomplete response (BIR). Non-ablated patients had NED in 90%, IR in 8.7% and BIR in 1.2%. No statistical difference was found between groups (p = 0.29). No patient had evidence of structural disease at the end of follow-up. Conclusions Our findings support the recommendation against routine RA in low-risk DTC patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
Endocrine - 80(2023), 3 vom: 29. März, Seite 606-611 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ilera, Verónica [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Differentiated thyroid cancer |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s12020-023-03306-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR051569493 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR051569493 | ||
| 003 | DE-627 | ||
| 005 | 20230521064758.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230521s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12020-023-03306-w |2 doi | |
| 035 | |a (DE-627)SPR051569493 | ||
| 035 | |a (SPR)s12020-023-03306-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ilera, Verónica |e verfasserin |0 (orcid)0000-0003-1724-9390 |4 aut | |
| 245 | 1 | 0 | |a Is radioiodine ablation with 1.1 GBq (30 mCi) 131I necessary in low-risk thyroid cancer patients? Results from a long-term follow-up prospective study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background In patients with low-risk differentiated thyroid cancer (DTC), remnant ablation with radioiodine (RA) after total thyroidectomy (TT) is controversial. No benefits have been demonstrated in terms of mortality or disease-free survival. Recent evidence found that RA did not improve mid-term outcomes. Purpose To evaluate initial response to treatment and long-term follow-up status in low-risk DTC patients after TT vs. TT + RA with 131I 1.11 GBq (30 mCi). Methods Prospective multicenter non-randomized study; 174 low-risk DTC that underwent TT were recruited an divided in two groups according to RA (87 ablated and 87 non-ablated). Response to treatment was evaluated at 6–18 months after thyroidectomy and at the end of follow-up with measurements of thyroglobulin, and anti-thyroglobulin antibodies levels, and neck ultrasonography. Results Baseline characteristics of both groups were similar. Ablated patients: median age 45.5 years, 84% females, 95.4% papillary thyroid carcinoma (PTC), mean tumor size 16 mm; non-ablated: median age 45 years, 88.5% females, 96.6% PTC, mean tumor size 14 mm. Response to initial treatment was similar between both groups, with < 2% of structural incomplete response. Final status was evaluated in 139 cases (median follow-up of 60 months). Among ablated patients, 82.8% had no evidence of disease (NED), 12% had an indeterminate response (IR) and 5% a biochemical incomplete response (BIR). Non-ablated patients had NED in 90%, IR in 8.7% and BIR in 1.2%. No statistical difference was found between groups (p = 0.29). No patient had evidence of structural disease at the end of follow-up. Conclusions Our findings support the recommendation against routine RA in low-risk DTC patients. | ||
| 650 | 4 | |a Differentiated thyroid cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Low-risk patients |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Remnant ablation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Response to treatment |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Califano, Inés |0 (orcid)0000-0002-7450-5832 |4 aut | |
| 700 | 1 | |a Cavallo, Andrea |0 (orcid)0000-0003-0959-950X |4 aut | |
| 700 | 1 | |a Faure, Eduardo |0 (orcid)0000-0003-1974-1485 |4 aut | |
| 700 | 1 | |a Vázquez, Adriana |0 (orcid)0000-0003-4514-4238 |4 aut | |
| 700 | 1 | |a Pitoia, Fabián |0 (orcid)0000-0002-2742-7085 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine |d [S.l.] : Springer, 1995 |g 80(2023), 3 vom: 29. März, Seite 606-611 |w (DE-627)SPR023714557 |w (DE-600)2074043-8 |x 1559-0100 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2023 |g number:3 |g day:29 |g month:03 |g pages:606-611 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12020-023-03306-w |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2023 |e 3 |b 29 |c 03 |h 606-611 | ||